Tiotropium Use

Paper Cited:

Zhou, Yumin & Zhong, Nan-shan & Li, Xiaochen & Chen, Shuyun & Zheng, Jinping & Dongxing, Zhao & Yao, Weimin & Zhi, Rongchang & Wei, Liping & He, Bingwen & Zhang, Xiangyan & Yang, Changli & Li, Ying & Li, Fenglei & Du, Juan & Gui, Jianping & Hu, Bin & Bai, Chunxue & Huang, Ping & Ran, Pixin. (2017). Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 377. 923-935. 10.1056/NEJMoa1700228.

Metrics:

GOLD Stage 1 and Stage 2 patients

FEV1 decline per year before bronchodilator use:
  53 +- 6 mL placebo
  38 +- 6 mL tiotropium
  15 mL difference (p-value = 0.06)

FEV1 decline per year after bronchodilator use:
  51 +- 6 mL placebo
  29 +- 5 mL tiotropium
  22 mL difference (p-value = 0.006)

Implementation:

-> tioBefore = FEV1 decline per year before bronchodilator use
-> If patient is using tiotropium, add tioBefore*(number of years) to the fev1_avg (FEV1 average) value

Caveats:

-> FEV1 decline per year before bronchodilator use was not statistically significant (p > 0.05)
-> Error bars (vari) not adjusted
-> Study was only over 2 years, our model is 11 years
-> Not verifying GOLD stage


